Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support.

Carlos Alberto Valdes Griffin StinsonOmar M SharafFabian Jimenez ContrerasAhmet BilgiliMustafa M AhmedJuan VilaroAlex M ParkerMohammad A Z Al-AniDaniel DemosJuan ArandaMark BleiweisThomas M BeaverEric I Jeng

Published in: Innovations (Philadelphia, Pa.) (2023)

High-risk patients with cardiogenic shock may be supported with Impella 5.5 beyond the FDA-approved duration without increased risk of complications or mortality.

Keyphrases

extracorporeal membrane oxygenation
left ventricular assist device
risk factors
cardiovascular events
drug administration
clinical practice
coronary artery disease